Earlier versions of GLP-1 drugs, such as exenatide (Byetta), increased the risk for pancreatic cancer or certain types of thyroid cancer and even instances of autoimmunity
Animal-model studies report improved tensile strength of healed wounds, reduced scar volume, and accelerated closure with GHK-Cu treatment
Personalized Approach: When PlexusDx Precision Peptide Genetic Testing Adds Value The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways
Ask about packaging upgrades
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics Advertisement Felix Alberta Blue Cross's 2026 drug pipeline report says GLP-1 receptor agonists remain a major cost driver for private plans and that overall GLP-1 therapy plan spend is unlikely to decline in future years, even as a semaglutide generic is expected in mid-2026 [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
The shedding typically begins two to three months after the weight loss initiates